



### **Appendix 3**

**This appendix was part of the submitted manuscript and has been peer reviewed.**

Appendix to: Jo HE, Prasad JD, Troy LK, et al. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. *Med J Aust* 2017; doi: 10.5694/mja17.00799 [Epub ahead of print].

## Appendix 3

### Competing interests

Helen Jo has received conference travel support from Boehringer Ingelheim.

Lauren Troy has received conference travel support from Intermune and Bayer, and has been involved in IPF clinical trials where medications were provided free of charge by the manufacturer.

Daniel Chambers has received speaker fees (Roche) and medical writer fees (Boehringer Ingelheim), income from appointment to the Boehringer Ingelheim and Roche advisory boards, and financial support from Boehringer Ingelheim for an ILD specialist nurse.

Nicole Goh has received conference travel support from Boehringer Ingelheim, speaker fees from Roche and Boehringer Ingelheim, income from appointment to the Boehringer Ingelheim and Roche advisory boards, and a research grant from Boehringer Ingelheim.

Margaret Wilcher has received conference travel support from Intermune and her institution has received funding for Capacity trials (Intermune).

Sally Chapman, Sally de Boer and Margaret Wilcher have received funding from Boehringer Ingelheim for named patient programs for the provision of nintedanib to IPF patients.

Yuben Moodley has received fees from Roche and Boeringher Ingelheim for writing and reviewing in this research area.

Christopher Grainge has received speaker fees from Roche and Boeringher Ingelheim, income from appointment to the Boehringer Ingelheim and Roche advisory boards, an unrestricted educational grant from Boehringer Ingelheim to support an ILD clinic, and his institution is performing contracted basic science research by Boehringer Ingelheim.

Paul Reynolds has received conference travel support from AstraZeneca. Ian Glaspole has received speaker fees from Roche and Boehringer Ingelheim, income for advisory board membership from AstraZeneca, Boehringer Ingelheim and Roche, and has been the principal investigator in clinical trials of IPF therapies (Roche, Intermune, Boehringer Ingelheim, Medimmune, Gilead, Actelion). His institution has received an equipment grant from Boehringer Ingelheim.

Ian Glaspole and Anne Holland have received an unrestricted educational grant from Roche to perform qualitative IPF research. Anne Holland has also received conference travel support from Boehringer Ingelheim.

Leonie Jones has received conference travel support and consultant fees from Roche.

Tamera Corte has received income from advisory board membership from Boehringer Ingelheim, Roche and AstraZeneca, speaker fees from Boehringer Ingelheim and Roche, and has been the principal investigator in clinical trials of IPF therapies (Roche, Intermune, Boehringer Ingelheim, Medimmune, Gilead, Actelion). Her institution has received unrestricted educational grants from Boeringher Ingelheim, Roche and Actelion.

Yuben Moodley, Nicole Goh, Christopher Grainge, Gregory Keir, Sally Chapman, Peter Hopkins, Ian Glaspole, Tamera Corte and Paul Reynolds are members of the Australian IPF Registry Steering Committee. Lung Foundation Australia has established the Australian IPF Registry with the generous support of a philanthropic family and unrestricted educational grants from Foundation partners Roche Products and Boehringer Ingelheim and from project partner Sanofi.